| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Anticancer; NF-κB;matrix metallopeptidase 2 (MMP2)/MMP9; p-AKT.
|
|---|---|
| ln Vitro |
7-Methoxy-1-tetralone (31.25-1000 μM; 48 h) suppresses LO2 and HepG2 cell growth [1]. HepG2 cells exposed to 40 μM, 100 μM, or 250 μM of 7-Methoxy-1-tetralone for 48 hours experience apoptosis, and the expression levels of c-Met, p-AKT, AKT, NF-κB, MMP2, and MMP9 proteins are regulated in the cells. [1].
|
| ln Vivo |
In HepG2 cell subcutaneously implanted tumor models, 7-Methoxy-1-tetralone (80, 120, or 160 mg/kg/d; intraperitoneal injection; 19 doses total) suppresses tumor growth [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HepG2 cells Tested Concentrations: 40 μM, 100 μM, and 250 μM Incubation Duration: 48 h Experimental Results: diminished the protein expression levels of c-Met, p-AKT, NF-κB, MMP2, and MMP9. Cell Proliferation Assay[1] Cell Types: LO2 and HepG2 cells Tested Concentrations: 31.25 μM, 62.5 μM, 125 μM, 250 μM, 500 μM, and 1000 μM Incubation Duration: 24 h, 48 h, and 72 h Experimental Results: demonstrated anti-proliferative activity of MT on LO2 and HepG2 cells. |
| Animal Protocol |
Animal/Disease Models: BALB/c nude mice (5weeks old) with subcutaneously (sc) implanted HepG2 cells[1]
Doses: 80, 120, or 160 mg/ kg/d Route of Administration: intraperitoneal (ip)injection; sacrificed after 19 days Experimental Results: Resulted the tumor inhibition rates of 40.57% (80 mg/kg), 51.43% (120 mg/kg), 79.43% (160 mg/kg), respectively. |
| References |
[1]. Wen Y, et al. 7-Methoxy-1-Tetralone Induces Apoptosis, Suppresses Cell Proliferation and Migration in Hepatocellular Carcinoma via Regulating c-Met, p-AKT, NF-κB, MMP2, and MMP9 Expression. Front Oncol. 2020 Feb 7;10:58.
|
| Additional Infomation |
7-Methoxy-3,4-dihydro-1(2H)-naphthone belongs to the tetrahydronaphthyl group of compounds. This study aimed to investigate the antiproliferative and antimigration effects of 7-methoxy-1-tetrahydronaphthone (MT) on hepatocellular carcinoma (HCC) cells. HCC cell viability was detected using the MTT assay; HCC cell apoptosis was detected by flow cytometry; HCC cell migration ability was assessed using a scratch assay; protein expression levels were detected by Western blot; the in vivo antitumor effect of MT was tested in a BALB/c nude mouse model, and pathological changes in tumor tissues were assessed by immunohistochemistry. Results showed that MT treatment significantly inhibited the proliferation and migration of HepG2 cells and induced HepG2 cell apoptosis. Western blot experiments showed that MT treatment inhibited the protein expression levels of c-Met, phosphorylated AKT (p-AKT), NF-κB, and matrix metalloproteinase 2 (MMP2)/MMP9 in HepG2 cells. Further in vivo animal experiments showed that MT treatment inhibited tumor growth of HepG2 cells in nude mice, but had no effect on body weight or liver and spleen organ indices. Immunohistochemical analysis of the dissected tumor tissues showed that MT treatment significantly inhibited the protein expression levels of NF-κB, MMP9, MMP2 and p-AKT. In summary, this study confirmed the anti-tumor effect of MT on hepatocellular carcinoma (HCC). MT may inhibit the progression of HCC by regulating mediators related to proliferation and migration in HepG2 cells, including c-Met, p-AKT, NF-κB, MMP2 and MMP9. [1]
|
| Molecular Formula |
C11H12O2
|
|---|---|
| Molecular Weight |
176.2118
|
| Exact Mass |
176.083
|
| CAS # |
6836-19-7
|
| PubChem CID |
81276
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
312.3±31.0 °C at 760 mmHg
|
| Melting Point |
59-63 °C(lit.)
|
| Flash Point |
145.8±18.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
2.79
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
200
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C([H])=C(C([H])=C([H])C=2C([H])([H])C([H])([H])C1([H])[H])OC([H])([H])[H]
|
| InChi Key |
GABLTKRIYDNDIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12O2/c1-13-9-6-5-8-3-2-4-11(12)10(8)7-9/h5-7H,2-4H2,1H3
|
| Chemical Name |
7-methoxy-3,4-dihydro-2H-naphthalen-1-one
|
| Synonyms |
7-Methoxy-1-tetralone; 6836-19-7; 7-METHOXY-3,4-DIHYDRONAPHTHALEN-1(2H)-ONE; 7-methoxy-3,4-dihydro-2H-naphthalen-1-one; 7-Methoxy-1,2,3,4-tetrahydronaphthalen-1-one; 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-; MFCD00001696; H4FZ2W25VZ;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (567.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6750 mL | 28.3752 mL | 56.7505 mL | |
| 5 mM | 1.1350 mL | 5.6750 mL | 11.3501 mL | |
| 10 mM | 0.5675 mL | 2.8375 mL | 5.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
